HK1206602A1 - Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same - Google Patents
Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same Download PDFInfo
- Publication number
- HK1206602A1 HK1206602A1 HK15107131.8A HK15107131A HK1206602A1 HK 1206602 A1 HK1206602 A1 HK 1206602A1 HK 15107131 A HK15107131 A HK 15107131A HK 1206602 A1 HK1206602 A1 HK 1206602A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- dry powder
- carrier
- inhalation formulation
- formulation
- inhalation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120063665A KR20130140358A (ko) | 2012-06-14 | 2012-06-14 | 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법 |
| KR10-2012-0063665 | 2012-06-14 | ||
| PCT/KR2013/004880 WO2013187626A1 (en) | 2012-06-14 | 2013-06-03 | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1206602A1 true HK1206602A1 (en) | 2016-01-15 |
Family
ID=49758405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15107131.8A HK1206602A1 (en) | 2012-06-14 | 2013-06-03 | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9283232B2 (enExample) |
| EP (1) | EP2861219A4 (enExample) |
| JP (1) | JP2015519394A (enExample) |
| KR (1) | KR20130140358A (enExample) |
| CN (1) | CN104363895A (enExample) |
| AU (1) | AU2013275113A1 (enExample) |
| BR (1) | BR112014030910A2 (enExample) |
| CA (1) | CA2876283A1 (enExample) |
| HK (1) | HK1206602A1 (enExample) |
| IL (1) | IL236198A0 (enExample) |
| IN (1) | IN2014DN11257A (enExample) |
| MX (1) | MX2014014755A (enExample) |
| NZ (1) | NZ703788A (enExample) |
| PH (1) | PH12014502746B1 (enExample) |
| RU (1) | RU2015100905A (enExample) |
| SG (1) | SG11201408292YA (enExample) |
| TW (1) | TWI565481B (enExample) |
| WO (1) | WO2013187626A1 (enExample) |
| ZA (1) | ZA201500208B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9360400B2 (en) | 2014-06-30 | 2016-06-07 | Proveris Scientific Corporation | Sampling apparatus for determining the amount and uniformity of a delivered dose of drug and related methods |
| WO2016052897A1 (en) * | 2014-09-30 | 2016-04-07 | Hanmi Pharm. Co., Ltd. | Dry powder for inhalation formulation having improved stability of combined active ingredients |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| KR20160117069A (ko) * | 2015-03-31 | 2016-10-10 | 한미약품 주식회사 | 복합 활성성분의 안정성이 개선된 흡입용 캡슐제 |
| BR112017023351B1 (pt) * | 2015-05-01 | 2023-11-28 | Board Of Regents, The University Of Texas System | Composição farmacêutica e uso da composição farmacêutica |
| CA3016890A1 (en) | 2016-03-09 | 2017-09-14 | Proveris Scientific Corporation | Methods for measuring dose content uniformity performance of inhaler and nasal devices |
| CN108066329B (zh) * | 2016-11-11 | 2021-11-16 | 江苏恒瑞医药股份有限公司 | 一种吸入用氟替卡松或其衍生物的微粒的制备方法 |
| ES2953293T3 (es) * | 2018-08-07 | 2023-11-10 | Norton Waterford Ltd | Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación |
| KR102696616B1 (ko) * | 2018-12-21 | 2024-08-20 | 한미약품 주식회사 | 흡입 제형용 건조 분말 및 이의 제조방법 |
| KR102330428B1 (ko) * | 2019-10-14 | 2021-11-24 | 한미약품 주식회사 | 흡입 제형용 건조 분말 및 이의 제조방법 |
| CN116033893A (zh) * | 2020-06-26 | 2023-04-28 | 迈兰制药英国有限公司 | 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂 |
| EP4228725A4 (en) | 2020-10-15 | 2024-11-06 | Proveris Scientific Corporation | SYSTEMS AND METHODS FOR INHALATOR TESTING |
| CN115266987B (zh) * | 2022-07-31 | 2023-06-30 | 浙江知一药业有限责任公司 | 治疗呼吸系统疾病的药物组合物 |
| CN115792071B (zh) * | 2022-12-01 | 2025-02-18 | 南京联智医药科技有限公司 | 一种噻格溴铵中间体的有关物质分析方法 |
| US12679516B2 (en) | 2023-05-17 | 2026-07-14 | Kenneth F. Flower | Boat lift |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9322014D0 (en) | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| GB0003935D0 (en) * | 2000-02-08 | 2000-04-12 | King S College London | Formulation for dry powder inhaler |
| DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| GB0312148D0 (en) | 2003-05-28 | 2003-07-02 | Aventis Pharma Ltd | Stabilized pharmaceutical products |
| SE527190C2 (sv) | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid |
| GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| EP2124915A2 (en) | 2007-02-19 | 2009-12-02 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid |
| US20100329996A1 (en) | 2007-09-12 | 2010-12-30 | Glaxo Group Limited | Novel Combination of Therapeutic Agents |
| WO2010007447A1 (en) | 2008-07-18 | 2010-01-21 | Prosonix Limited | Process for improving crystallinity |
| EP2328556A4 (en) * | 2008-07-30 | 2013-11-20 | Stc Unm | FORMULATIONS WITH LARGE SUPPORT PARTS FOR AEROSOLS FOR THE INHALATION OF DRY POWDER |
| TR201000681A2 (tr) * | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | İnhalasyon yoluyla alınan kuru toz formülasyonları. |
-
2012
- 2012-06-14 KR KR1020120063665A patent/KR20130140358A/ko not_active Ceased
-
2013
- 2013-06-03 WO PCT/KR2013/004880 patent/WO2013187626A1/en not_active Ceased
- 2013-06-03 RU RU2015100905A patent/RU2015100905A/ru not_active Application Discontinuation
- 2013-06-03 CA CA2876283A patent/CA2876283A1/en not_active Abandoned
- 2013-06-03 NZ NZ703788A patent/NZ703788A/en not_active IP Right Cessation
- 2013-06-03 JP JP2015517171A patent/JP2015519394A/ja active Pending
- 2013-06-03 HK HK15107131.8A patent/HK1206602A1/xx unknown
- 2013-06-03 CN CN201380030898.0A patent/CN104363895A/zh active Pending
- 2013-06-03 IN IN11257DEN2014 patent/IN2014DN11257A/en unknown
- 2013-06-03 BR BR112014030910A patent/BR112014030910A2/pt not_active IP Right Cessation
- 2013-06-03 SG SG11201408292YA patent/SG11201408292YA/en unknown
- 2013-06-03 AU AU2013275113A patent/AU2013275113A1/en not_active Abandoned
- 2013-06-03 US US14/402,548 patent/US9283232B2/en not_active Expired - Fee Related
- 2013-06-03 MX MX2014014755A patent/MX2014014755A/es unknown
- 2013-06-03 EP EP13804439.1A patent/EP2861219A4/en not_active Withdrawn
- 2013-06-13 TW TW102120909A patent/TWI565481B/zh not_active IP Right Cessation
-
2014
- 2014-12-09 PH PH12014502746A patent/PH12014502746B1/en unknown
- 2014-12-11 IL IL236198A patent/IL236198A0/en unknown
-
2015
- 2015-01-13 ZA ZA2015/00208A patent/ZA201500208B/en unknown
- 2015-06-22 US US14/746,225 patent/US9549936B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015100905A (ru) | 2016-08-10 |
| NZ703788A (en) | 2016-10-28 |
| JP2015519394A (ja) | 2015-07-09 |
| PH12014502746A1 (en) | 2015-02-02 |
| MX2014014755A (es) | 2015-02-24 |
| US20150157566A1 (en) | 2015-06-11 |
| PH12014502746B1 (en) | 2015-02-02 |
| KR20130140358A (ko) | 2013-12-24 |
| EP2861219A1 (en) | 2015-04-22 |
| US9283232B2 (en) | 2016-03-15 |
| IL236198A0 (en) | 2015-01-29 |
| WO2013187626A1 (en) | 2013-12-19 |
| BR112014030910A2 (pt) | 2017-06-27 |
| IN2014DN11257A (enExample) | 2015-10-09 |
| SG11201408292YA (en) | 2015-01-29 |
| AU2013275113A1 (en) | 2015-02-05 |
| US9549936B2 (en) | 2017-01-24 |
| US20150283151A1 (en) | 2015-10-08 |
| TW201402154A (zh) | 2014-01-16 |
| TWI565481B (zh) | 2017-01-11 |
| CN104363895A (zh) | 2015-02-18 |
| CA2876283A1 (en) | 2013-12-19 |
| ZA201500208B (en) | 2016-10-26 |
| EP2861219A4 (en) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9549936B2 (en) | Method for preparing dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide | |
| CN105101955B (zh) | 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物 | |
| EP2806855B1 (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| EP3203983B1 (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| CN105338967A (zh) | 包含布地奈德和福莫特罗的药物组合物 | |
| US12491156B2 (en) | Carrier particles for dry powder formulations for inhalation | |
| RU2422144C2 (ru) | Применение солей тиотропия для лечения тяжелых форм персистирующей астмы | |
| EA015353B1 (ru) | Применение солей тиотропия для лечения персистирующей астмы средней тяжести | |
| EP3203984B1 (en) | Pharmaceutical composition containing budesonide and formoterol. | |
| HK40064779A (en) | Novel carrier particles for dry powder formulations for inhalation | |
| KR20160038767A (ko) | 복합 활성성분의 안정성이 개선된 흡입 제형용 건조분말 |